%0 Journal Article %J Gastroenterology Review/Przegląd Gastroenterologiczny %@ 1895-5770 %V 10 %N 4 %D 2015 %F Petryszyn2015 %T Economic implications of biological therapy for Crohn’s disease %X In the early 90s American authors estimated that if a theoretical new drug was introduced that was capable of changing the natural course of the disease and reducing direct non-drug medical costs (including hospitalisation and surgery) by 20%, despite doubling the overall drugs bill, there would still be a reduction in total direct medical costs of Crohn’s disease by 13%. Infliximab proved to be efficacious in reducing and maintaining remission in moderate to severe active Crohn’s disease and/or fistulising Crohn’s disease. A higher acquisition cost still remains its major limitation. Currently only the use of infliximab in case of treatment for flares seems to be cost-effective. However, this statement may be modified in the near future. %A Petryszyn, Paweł W. %A Paradowski, Leszek %P 197-202 %9 journal article %R 10.5114/pg.2015.55749 %U http://dx.doi.org/10.5114/pg.2015.55749